Company: VRCA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001660334-25-000006
Chunk: 13

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
41 1 Treasury stock, at cost, 10,514 shares as of September 30, 2025 and December 31, 2024— — Additional paid-in capital299,798 297,166 Accumulated deficit(316,839)(307,027)Total stockholders’ deficit(17,040)(9,860)Total liabilities and stockholders’ deficit$40,896 $54,134 

The accompanying notes are an integral part of these financial statements.

2

Table of Contents

VERRICA PHARMACEUTICALS INC.

STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

(Unaudited)

For the Three Months EndedSeptember 30,For the Nine Months EndedSeptember 30,2025202420252024Revenue:Product revenue, net$3,607 $(1,865)$11,563 $6,259 License and collaboration revenue10,737 84 18,922 963 Total revenue14,344 (1,781)30,485 7,222 Operating expenses:Cost of product revenue754 351 1,517 1,257 Cost of collaboration revenue355 84 523 858 Selling, general and administrative9,403 16,083 27,103 48,944 Research and development2,205 2,405 6,335 10,672 Total operating expenses12,717 18,923 35,478 61,731 Income (loss) from operations1,627 (20,704)(4,993)(54,509)Other income (expense):Interest income159 221 724 1,212 Interest expense(2,094)(2,376)(6,428)(7,063)Change in fair value of derivative liability34 — 886 — Other expense— (1)(1)(17)Total other expense, net(1,901)(2,156)(4,819)(5,868)Net loss$(274)$(22,860)$(9,812)$(60,377)Net loss per share, basic and diluted$(0.03)$(4.88)$(1.03)$(12.96)Weighted-average common shares outstanding, basic and diluted9,490,0834,680,5439,489,1734,659,788

The accompanying notes are an integral part of these